(HealthDay News) — Mitomycin gel appears safe and effective for patients with upper tract urothelial cancers (UTUCs) in the real world, according to research published in Urologic Oncology.
Researchers studied patients treated with mitomycin gel at 15 institutions, analyzing practice patterns, efficacy, and adverse effects. A total of 132 patients were included, and most had biopsy-proven low-grade UTUC.
The researchers observed considerable variation in practice patterns. However, antegrade instillation via a percutaneous nephrostomy was the most common administration technique.
Continue Reading
When mitomycin gel was used in the adjuvant setting, 69% of patients were disease-free at the time of first endoscopic evaluation. When mitomycin gel was used in the chemoablative setting, 37% of patients were endoscopically clear on the first evaluation.
The complete response rate was higher in patients with smaller tumor size prior to induction. A 70% complete response rate was seen in association with low-volume (<1 cm) residual disease.
Maintenance doses were used in 27% of cases. New-onset, clinically significant ureteral stenosis was seen in 23% of patients.
Two study authors disclosed financial ties to biopharmaceutical companies, including UroGen Pharma, the manufacturer of mitomycin gel (UGN-101).
Abstract/Full Text (subscription or payment may be required)
